During the second quarter
ARR was 33% higher year-over-year at $614 million and SaaS
ARR was 50% higher year-over-year at $418 million.
As culled from the "issues paper" released by the ERC, the regulatory period will still be over four-year rolling period with annual adjustment on the
ARR of the DUs; hence, that will also entail changes or movements in the charges they will pass on to ratepayers.
John Lawrie said
ARR Craib has been able to deliver this as it operates the largest general haulage fleet in Scotland with more than 225 vehicles from small vans to 44-tonne artic lorries, and 400 trailers, including curtain-siders, flatbeds, bulk tippers, double-deckers and lowloaders.
RingCentral Office[R]
ARR increased 36% year over year to USD 694 million.
Championship chairman, Gordon Adam, said: "
ARR Craib have been fundamental in the growth and popularity of the Scottish Rally Championship in recent times and the series, organisers and events would like to extend their heartfelt thanks to the firm and particularly Eddie Anderson for their support over the years.We have been able to provide a fantastic championship for our competitors and the incentives we have on offer have been unrivalled in the sport at a national level.
Concert Band: The band closed out the show with "The American Red Cross",
arr. D.
It is generally accepted that both the plasma renin and aldosterone levels tend to fall with advancing age and plasma renin decreases more than aldosterone; consequently, the
ARR increases in the elderly [1].
In that analysis, the
ARR was greater (~3%
ARR over three years) in patients with a history of heart attack within two years compared to those whose heart attack was more than two years past (
ARR 1%).
Cinq lments de soutien aux groupes terroristes ont t
arr?ts dimanche Boumerd?s et Ain Defla par des dtachements de l'Arme nationale populaire (ANP), indique lundi le minist?re de la Dfense nationale dans un communiqu.
Apical root resorption (
ARR) delivers with a multifactorial etiology.
Celgene's Phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (
ARR), compared to weekly interferon (IFN) [beta]-1a (Avonex).